Gyre Therapeutics, Inc. (GYRE): Operating Cash Flow
$1.01M
Year ended 2025-12-31
-54.4%
3-year compound annual growth
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.01M | n/m | 2026-03-13, From 2025-01-01 |
| 2024-12-31 | -$3.64M | n/m | 2026-03-13, From 2024-01-01 |
| 2023-12-31 | $25.89M | +142.5% | 2025-03-17, From 2023-01-01 |
| 2022-12-31 | $10.68M | n/m | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | -$83.75M | n/m | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | -$55.05M | n/m | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | -$43.61M | n/m | 2021-03-04, From 2019-01-01 |
| 2018-12-31 | -$28.55M | n/m | 2020-02-20, From 2018-01-01 |
| 2017-12-31 | -$19.94M | n/a | 2019-03-08, From 2017-01-01 |
| No annual figure between 2013-12-31 and 2017-12-31. | |||
| 2013-12-31 | -$40.61M | n/m | 2014-03-14, From 2013-01-01 |
| 2012-12-31 | -$64.24M | n/m | 2014-03-14, From 2012-01-01 |
| 2011-12-31 | -$83.72M | n/m | 2014-03-14, From 2011-01-01 |
| 2010-12-31 | $138.30M | n/m | 2013-03-15, From 2010-01-01 |
| 2009-12-31 | -$24.27M | n/a | 2012-03-06, From 2009-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $1.01M | n/m |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | -$162.44M | n/m |
| Xencor Inc (XNCR) | 2025-12-31 | -$135.12M | n/m |
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $238.54M | n/m |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | -$1.60M | n/m |
| Zymeworks Inc. (ZYME) | 2025-12-31 | -$33.01M | n/m |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | -$206.0K | n/m |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $43.47M | -10.8% |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | -$75.37M | n/m |
Compare GYRE, URGN, XNCR, TBPH side by side · Screen every company in Pharmaceutical Preparations ↗